Pages that link to "Q28243071"
Jump to navigation
Jump to search
The following pages link to PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma (Q28243071):
Displaying 50 items.
- Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway (Q21135589) (← links)
- Mutational profiling of kinases in glioblastoma (Q21261249) (← links)
- Carboxy-Terminal Modulator Protein (CTMP) is a mitochondrial protein that sensitizes cells to apoptosis (Q24321723) (← links)
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer (Q24338724) (← links)
- Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics (Q24595882) (← links)
- Tumours with PI3K activation are resistant to dietary restriction (Q24650286) (← links)
- Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer (Q24653934) (← links)
- Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway (Q24813788) (← links)
- Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies (Q26741028) (← links)
- Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer (Q26778349) (← links)
- PI3K and AKT: Unfaithful Partners in Cancer (Q26781367) (← links)
- Profile of neratinib and its potential in the treatment of breast cancer (Q27012540) (← links)
- Monoclonal antibodies for the treatment of cancer (Q27025966) (← links)
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancer (Q27646556) (← links)
- Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit (Q27646654) (← links)
- The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations (Q27649316) (← links)
- Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling (Q27851446) (← links)
- PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. (Q27851582) (← links)
- The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations (Q27851644) (← links)
- Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies (Q27853149) (← links)
- PI3K mutations in breast cancer: prognostic and therapeutic implications (Q28081992) (← links)
- Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2 (Q28085004) (← links)
- Current development of mTOR inhibitors as anticancer agents (Q28255366) (← links)
- Oncogenic mutations of PIK3CA in human cancers (Q28284802) (← links)
- Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system (Q28484040) (← links)
- Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel (Q28541288) (← links)
- Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors (Q28729079) (← links)
- Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes (Q28730141) (← links)
- Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics (Q28751743) (← links)
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism (Q29547302) (← links)
- PI3K pathway alterations in cancer: variations on a theme (Q29615530) (← links)
- The determinants of head and neck cancer: Unmasking the PI3K pathway mutations (Q30365726) (← links)
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies (Q30431388) (← links)
- Absence of AKT1 mutations in glioblastoma (Q30439629) (← links)
- The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration (Q30494570) (← links)
- Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. (Q30857631) (← links)
- Mutations in PIK3CA are infrequent in neuroblastoma (Q33248957) (← links)
- EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation (Q33258056) (← links)
- Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities (Q33315604) (← links)
- Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. (Q33382682) (← links)
- A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer (Q33407185) (← links)
- A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene (Q33436440) (← links)
- PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast (Q33509688) (← links)
- High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast (Q33515565) (← links)
- Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer (Q33552870) (← links)
- PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma (Q33572680) (← links)
- Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice (Q33592917) (← links)
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer (Q33605111) (← links)
- PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer (Q33610437) (← links)
- Detection of cancer DNA in plasma of patients with early-stage breast cancer. (Q33624889) (← links)